RadNet (RDNT) Q2 2024 earnings summary

Executive summary

• Achieved record Q2 2024 revenue of $459.7 million, up 13.9% year-over-year, and record Adjusted EBITDA of $72.3 million, up 19.7%, driven by strong demand, advanced imaging, digital health expansion, and acquisitions, with 398 centers in operation as of June 30, 2024.

• Digital Health segment revenue rose 36.4% to $15.8 million, with AI revenue up 136.6% to $5.6 million, driven by EBCD AI-powered mammography and rapid adoption.

• Net loss attributable to common stockholders was $3.0 million for Q2 2024, compared to net income of $8.4 million in Q2 2023, primarily due to higher interest expense and debt extinguishment costs.

• Major expansion into Houston, Texas, with two acquisitions totaling 13 imaging centers, and continued growth in joint venture partnerships, now with 37.4% of centers in health system partnerships.

• Increased 2024 guidance for revenue, Adjusted EBITDA, and free cash flow based on strong performance and ongoing investments in AI, de novo centers, and joint ventures.

Financial highlights

• Q2 2024 revenue: $459.7 million (+13.9% YoY); Adjusted EBITDA: $72.3 million (+19.7% YoY); Adjusted EBITDA margin: 15.7% (+76 bps YoY).

• Imaging Center segment: $443.9 million revenue (+13.2% YoY), $69.1 million Adjusted EBITDA (+16.9% YoY); Digital Health: $15.8 million revenue (+36.4% YoY), $3.3 million Adjusted EBITDA (+135.2% YoY).

• Adjusted EPS: $0.16 (Q2 2024) vs $0.10 (Q2 2023); Net loss of $3.0 million (Q2 2024) vs net income of $8.4 million (Q2 2023), due to one-time items.

• Cash and cash equivalents at June 30, 2024: $741.7 million, up from $342.6 million at year-end 2023.

• Six-month revenue: $891.4 million (+12.2% YoY); Six-month Adjusted EBITDA: $130.8 million (+20.4% YoY).

Outlook and guidance

• 2024 revenue guidance raised to $1.685–$1.735 billion; Adjusted EBITDA to $257–$267 million; free cash flow to $72–$80 million.

• Capital expenditures for Imaging Center segment increased to $135–$145 million; digital health segment guidance unchanged.

• Medicare reimbursement cuts of $6–$8 million expected in 2025, but offset by commercial and capitated payer increases.

• Sufficient liquidity and borrowing capacity to fund operations and future acquisitions over the next twelve months.

• Digital Health segment anticipated to generate net losses for the next several years as investments in AI and cloud-based solutions continue.